All the Thank Yous – Wrapping Up the 1st Microscopes & Machines Conference

Posted Posted in Blog

Thank you.

When we first began working on Microscopes and Machines we were driven to create a truly meaningful cannabis conference, one that united people around a shared focus on the healing potential of the plant, not just its profit potential.

This past Saturday was the realization of the cannabis nerd conference of our dreams, a living demonstration of what collaboration and connection can look like and mean, particularly at this early stage of the industry. 

While the conference may be over, our mission to be dope to one other continues, and in that spirit we wanted to send a thank you note to everyone who played a part in making this conference a reality.

– Thank you to everyone who attended; without exaggeration you’re the reason this conference existed at all. People came from near and far (we talked to multiple attendees who traveled from across the country) to contribute their own expertise and energy and we were inspired by the turnout. Thank you.

– Thank you to our speakers. We were humbled to have some of the most highly-regarded thinkers, practitioners, and inventors in hemp and cannabis (and psychedelics) join us. We wanted to give our speakers a chance to go beyond their “usual” conference material and instead think more broadly and share their vision for the future and they all responded with incredible power and wisdom. Thank you.

– Thank you to our sponsors. Each of our sponsors provided much more than a name and a logo, they provided their own expertise and even their own resources to help make this conference truly truly memorable and meaningful. Thank you.

– A very special thank you to Inclusive Cannabis for being such a strong support as our production partner, your team played a pivotal role in bringing this vision to life. We are so grateful to you. Thank you. 

– Thank you to the community. The cannabis industry shouldn’t operate in a vacuum, which is why we chose to hold our event in downtown Los Angeles, and why we’re donating proceeds to The Giving Spirit. We encourage you to connect with them and consider volunteering and/or donating to The Giving Spirit as part of your own corporate social responsibility programs. Thank you.

– Thank you to the comedians that kicked off the Vibratorium after party and elevated all the vibes with laughter, Kalea McNeill, Rachel “Wolfie” Wolfson, Sara Weinshenk, and Justin Martindale, thank you. To the musicians, Courtney Lemmon & Friends, you rocked it. Our gratitude to you for an epic set and awesome cover of “Hey Jude” to close out the Vibratorium. Thank you.

– Thank you to everyone. From the artists doing live installations, Asia Taber and 3C Farms, your cannabis kaleidoscope and water immersed cannabis centerpieces were truly inspired & Linzy Miggantz your live cannabis painting brought much heart and beauty to our day. To the chefs who prepared our delicious vegan food, lunch by Leaf Over Beef and an Ayurvedic Indian dinner by Ayur Ras, thank you. And to the staff that helped ensure we had such a beautiful place to gather in and beyond, so many people came together to make this happen. Thank you to you all.

While the first Microscopes & Machines may be over, we’re carrying the knowledge and energy we gained from the conference forward with us, and we hope you are too. Over the next months we’ll be hard at work crafting our next venture, and will be posting content from the conference for you to revisit and reference in the days to come. Stay tuned to our Instagram channel for those updates and once again – thank you. 

Be Dope To One Another.

With love & gratitude,

A Dope Conference Company

“Scale Up or Go Niche” Dustin Powers Advice to Manufacturers and Dedication to Open-Source Cannabis

Posted Posted in Blog

Like many in the industry, Dustin Powers never planned on making cannabis his career. But whether he found the plant or the plant found him, the plant is now his life’s work.

Powers was only a casual cannabis consumer when he moved to Washington State shortly before the state coincidentally legalized cannabis in 2012. A couple twists of fate later and Powers found himself working for the renowned Skunk Pharm Research collective.

Powers was fascinated by Skunk Pharm’s meticulously scientific approach to cannabis and revolutionary model of sharing knowledge communally. “That’s where I learned the open source model,” he said in our interview. “That’s how I got really deep into cannabis science, the extraction side of things. It all snowballed from there.” 

As Powers continued to learn and experiment, eventually striking out on his own, that snowball came to include multiple pioneering breakthroughs in the industry, from the beginnings of ethanol extraction to advancements in pesticide remediation.

Crucially though, throughout his successes he’s remained dedicated to an open-source model of cannabis science. That dedication is what led him to launch the cannabis manufacturing forum Future4200, and to begin his latest venture, Good Life Gang, a members-only community committed to supporting each other with knowledge, networking, and other resources.

If that approach seems radical, especially in the face of cannabis’ rapid corporatization, that’s exactly his intention. Powers see the globalization of cannabis as eventually inevitable, and so in order to survive manufacturers will either have to master their craft, or master mass scale production.

“If you look at consumers now, they all want distillate and vape pens, and the name of that game is scale up or go home.

That really is it. You either scale, or you go really niche, like a really high end propane extract. Those things are harder to replicate at scale, especially if you’re working directly with the farmer, so you have some potential staying power as the price falls out.”

No matter which side a manufacturer chooses, mass scale or niche concentration, Powers deeply believes that success never comes alone, and so Powers is excited to not only speak at the Microscopes and Machines conference, but have the chance to connect with and answer questions from the community.

We hope that you’ll join us in Los Angeles on July 27 for the opportunity to talk to Powers and our entire speaker line-up. For tickets and more information,

Dr. Sue Sisley Is Suing the DEA Over Cannabis Research, Here’s Why

Posted 3 CommentsPosted in Blog

51 years ago the U.S. government named the University of Mississippi as the only legal supplier of medical cannabis. Accordingly, generations of scientists were forced to obtain a highly coveted DEA Schedule 1 research license merely for the privilege of being able to purchase whatever cannabis the University decided to provide them.

Three years ago the DEA announced it recognized researcher demand for a larger and diverse variety of cannabis and that it would soon be increasing the number of federally authorized growers. Since then, exactly zero additional growers have been named despite over 30 applications.

Three weeks ago Dr. Sue Sisley filed a lawsuit against the DEA, alleging that the government enforced monopoly at the University of Mississippi was harming researchers by limiting legal access to a plant, in turn harming patients who would remain without potentially critical clinical research information and access to potential new medicines.

“Maintaining only one federally legal drug supply for any clinical trials in the US has been a huge impediment to research because it’s not allowing scientists access to necessary options. We can’t just study from one supplier who seems to be limited from purchasing new genetics. And when there’s a monopoly for this many decades, it tends to breed apathy. There’s no real drive to respond to the public, to be responsive to the demands of scientists, no real need to innovate in the direction of what patients want.”

Dr. Sisley is well-positioned to file the suit. As one of the few people to hold two different DEA Schedule I licenses as researcher & analytical lab, Dr. Sisley has been carrying out the only FDA-approved randomized controlled trial in the world examining safety/efficacy of whole plant marijuana in combat veterans with severe post traumatic stress disorder, PTSD, for several years.

As the PTSD study concluded and Dr. Sisley began preparing to publish the results, she unblinded the data and quickly came to believe that the quality of cannabis provided by the University of Mississippi had negatively affected the study’s efficacy data.

“Most scientists end up with this mishmash of different strains (including stem sticks, leaves etc) – all of it seems to get thrown into a grinder in overzealous effort to standardize the study drug batches for clinical trials. I’m arguing that by doing that, they’re overprocessing the plant and decimating the natural efficacy contained in the flowering tops. Further, in controlled trials we issue patients the study drug by weight.

So if the weight of study drug is being augmented with this extraneous plant material instead of just the dry flower/bud,” Dr. Sisley explained, “common sense suggests how this dilution could harm the outcomes of efficacy data”.

Without the ability to legally obtain cannabis from a range of federally legal suppliers who would be motivated to provide better options, service and quality, and without specific access to a diverse variety of strains (more similar to the thousands of phenotypes readily available throughout the US regulated markets) that could be studied to see if they offered varying treatment potential, Dr. Sisley maintains that scientists are unjustly handcuffed.

While the lawsuit is focused on breaking of the University of Mississippi’s supplier monopoly, Dr. Sisley knows firsthand that this issue is only a strand in a larger web of challenges that cannabis researchers face.

In addition to extraordinarily limited access to research material, studies proposing to examine the potential harms of cannabis are often quickly approved by the government, while studies aimed at the efficacy of cannabis are routinely stalled.

And by refusing to provide any whole cannabis flower which can eventually be sold as a prescription medicine to researchers for study in FDA PHASE 3 Trials, the government is disadvantaging those interested in researching whole plant treatments in favor of large pharmaceutical companies who are only looking to isolate specific patentable cannabis compounds.

Dr. Sisley recognizes that even if her lawsuit is successful the results will still be a long time coming. It will take newly DEA licensed BULK MANUFACTURERS years to get up and running, all while other countries with already fully developed medical cannabis supply chains like Canada, Israel, Australia, and others continue to pull ahead of the U.S. in the race to take the lead in clinical cannabis medicine research.

“That’s why I spend so much time educating about the limitations of this monopoly and the fact that if we could ever license other growers for research and have options for scientists, it could create a renaissance of cannabis research in the US, which is we could, you know, regain our rightful place at the helm of the most important cannabis clinical trials in the world.”

While the lawsuit progresses through the court system Dr. Sisley is actively gearing up for a phase two of the PTSD study, including looking for a private partner to help her redo the study with real world cannabis flower. 

“I believe that efficacy data would be significantly different if these patients were allowed to self-titrate real world cannabis,” explained Dr. Sisley.

And true to her word, she’ll be continuing her mission to educate others about the current medical cannabis monopoly by delivering one of the keynote addresses at the Microscopes & Machines conference, taking place in Los Angeles on July 27. To see Dr. Sisley along with a diverse array of other speakers and cannabis experts, click here for tickets

The Complete Microscopes & Machines Speaker Line-Up

Posted Posted in Blog

When we set out to create this conference, we believed that there were two crucial but often overlooked topics in the industry

1) The need to refocus on the healing potential of cannabis (Microscopes)

2) How to scale an industry already facing massive bottlenecks (Machines)

While vital, we came to realize that these topics are often under-represented at cannabis conferences because it’s frankly very difficult to find verified experts on these topics, and even more difficult to convince those experts to take time away from their practices.

Thankfully, many experts believed in our mission as much as we did, and the end result is a speaker line-up that we can say without exaggeration is unprecedented. Featuring some of the most highly-regarded thinkers, practitioners, and inventors in hemp and cannabis, these are the people directly shaping the industry’s landscape.

Microscopes Track:

Dr. Jeff Chen: The Founder and Executive Director of the UCLA Cannabis Research Initiative, one of the first university programs dedicated to the study of cannabis.

Dr. Pierre Geoffroy: After 25 of global pharmaceutical experience, Dr. Geoffroy is now a leading physician who specializes in using cannabis to treat Substance Abuse Disorder.

Sheila Gibson, Esq.: Sheila Gibson brings deep IP experience to helping independent cannabis operators hold their ground as corporate interests attempt to takeover.

Dr. Pepper Hernandez: Dr. Pepper Hernandez is at the forefront of a new kind of holistic medicine that uses cannabis as a therapeutic instrument.

​Madison Margolin: An experienced cannabis journalist, Margolin is Co-Founder of the recently launched psychedelics magazine, Double Blind.

Dr. Michael Masterman-Smith: Dr. Michael Masterman-Smith is an entrepreneurial scientist, cancer biologist, pharmacologist, and healthcare expert who holds the distinction of being one of the co-discoverers of cancer stem cells.

Nicole Howell Neubert, Esq.: A co-founder of Clark & Neubert LLP, Neubert is one of California’s most effective and respected cannabis business and regulatory attorneys.

John Clayborn Poss: John Poss serves as The CEO & Chairman of GB Sciences, Inc., a cutting edge cannabis cultivation and biopharmaceutical research company.

Dr. Michele Ross: Dr. Ross holds a PhD in Neuroscience and has been active in psychedelic research and drug policy reform for over a decade. 

Dr. Stuart Silverman: A faculty member of the UCLA Cannabis Research Initiative, Dr. Silverman is also a Professor at both Cedars Sinai Medical Center and the David Geffen School of Medicine at UCLA. He has published more than 200 peer reviewed papers.

Dr. Sue Sisley: One of the few federally-regulated cannabis researchers in the world, Dr. Sue Sisley recently filed a lawsuit against the DEA.

Dr. Andrea Small-Howard: The Chief Science Officer at GB Sciences, Inc., Dr. Small-Howard is working to advance clinical research on medicinal applications of cannabinoid compounds.

Microscopes Track:

Dr. Wyeth Callaway: Now an independent consultant, Dr. Callaway was previously at Jetty Extracts, where he helped the cannabis manufacturer increase capacity 10 times

Noah Cook: Noah Cook is at the forefront of industrial cannabis applications in a regulatory environment. His work on ethanol extraction and recovery systems is now world renowned.

Boris Kogon: The Founder of BizzyBee, Boris Kogon specializes in the process of choosing a solvent and recovering that solvent at scale.

Dustin Powers: The founder of GoodLifeGang and the Future4200 Forum, Dustin has pioneered multiple breakthroughs in the industry, from the beginnings of ethanol extraction to pesticide remediation.  

Ace Shelander P.E.: The Co-Founder of Beaker & Wench, Ace has brought wiped-film evaporation and machine design to a new level of excellence.

Harrison Spence: The Co-Founder of Accurate Extraction and Head of R&D at JVI, Spence is an industry leader in large-scale production facilities renowned for developing single body dual stage condensing for wipe film Distillation.

Andy Spoone: The Co-Founder and COO of Sierra Labs, Spoone is a widely regarded leader in developing technology solutions to accelerate compliance in Healthcare and Life Science.  

Ken White: The former Chief Scientist and Director of Manufacturing at Cura (Select), White has developed many innovative products such as pure THCA and CBD Isolates as well as water soluble formulations.

There will be opportunities to ask all of our speakers questions, and a special break out Testing Panel towards the end of the day where attendees will have the opportunity to have a direct Q&A with some of the most well-known names in California Cannabis Testing Regulations. Aaron Riley of Cannasafe, Addison Demoura of Steep Hill, Josh Wurzer of SC Labs, and Swetha Kaul of Cannalysis will help demystify some of the common unknowns. Consultations with these speakers normally run in the thousands of dollars, so be sure to come prepared with your best questions!

Please visit our Schedule page for details about the panels each speaker will be on, and click here to buy tickets. We hope to see you there!

Creating a New Kind of Cannabis Conference

Posted Posted in Blog

Cannabis conferences that feel more like product placement opportunities. “Networking” events that end up filling trash cans with discarded business cards. Insights that turn out to have no practical application.

We’ve all been there – which is why we’re so dedicated to making Microscopes & Machines an antidote to your typical boring conference. We’ve been busy creating in-depth content to help highlight what makes us special, but we also know how busy you are, so we wanted to take a moment to just plainly lay out why this is a one-of-a-kind cannabis and help conference.

1) Speakers: 16 speakers over two tracks featuring the experts who are actively creating the future of cannabis medicine and manufacturing. Click here for a full list of speakers.

2) Vibratorium: Live entertainment, CBD mocktails, special treats, and giveaways to close out the event in style. Click here to learn more.

3) Networking: Take advantage of our unprecedented array of experts to make connections and ask questions normally reserved for paid consultations.

4) The Giving Spirit: 10% of proceeds will be donated to The Giving Spirit, which provides immediate aid to homeless people and families in L.A. Click here to learn more.

5) Organic Meals: There’s no such thing as a good time without good food: Breakfast snacks, lunch and dinner will be served by local, organic restaurants.

6) Technology: Get a sneak peek at some of the latest innovations in cannabis manufacturing and technology, shown here for the first time ever.

The final piece that is going to make this conference truly special is you. We hope you’ll join us in Los Angeles on July 27, and in the meantime, don’t hesitate to reach out with any questions or requests.

Special discounts available for military and social equity applicants/owners

For more details and to purchase tickets, visit: www.microscopesandmachines.com

Press inquiries: christian@adopeconference.com

We look forward to seeing you at the conference!

Come Vibe With Us at the Microscopes & Machines After Party

Posted 1 CommentPosted in Blog

We very genuinely believe that we’re at an inflection point in cannabis, and so we’ve designed the Microscopes and Machines conference to be enlightening, empowering, and filled with actionable insights.

At the same time, while steering the future of the cannabis industry is serious business, it’s also a cause for celebration. It’s in that spirit that we’ve created the Vibratorium, which will give every attendee a way to relax into the evening and expand their minds, palates, and networks.

As with everything we do, we aren’t designing the Vibratorium to be your average “networking” event. We’re designing this to be a creatively fueled mini-festival that allows everyone to vibe off each other, making more meaningful connections in the process, and we’re doing that through three main channels.

THE SPACE

The Vibratorium will take place in the enchanting Sunset Dining Room upon conclusion of the presentations.

This space is beautiful, interesting, and has deep historical roots, having served as a brothel, cannabis grow, ice-cream factory, and more over the years. Frankly we can’t think of a more fitting place to spark memorable experiences and connections.

THE ENTERTAINMENT

For an industry with literal and figurative roots in creativity, cannabis conferences can often be surprisingly dull; un-vibed, if you will.

To counter that, we’re be providing extraordinary entertainment.

First, we’ll be joined by some of the best cannabis-loving comedians out there, including:

Jessimae Peluso: Comedian, cast member of MTV’s Girl Code, Alzheimer’s advocate and host of the Sharp Tongue Podcast. Check her out here.

Rachel Wolfson (aka Wolfie): Comic, creator of @WolfieMemes, host of the Chronic Relief podcast. Check her out here.

Sara Weinshenk: Comedian, writer, host of the Shenk podcast. Check her out here.

Hosting this All-Star lineup will be Kalea Mcneil, who plays Hanifa on The CW’s Crazy Ex-Girlfriend and is the host and curator of #winedownwednesday.

THE ENTERTAINMENT CONTINUES

After the astonishing comedy hour, we’ve gathered a crew of some of West LA’s best musicians to perform jazz fusion tunes with some pop appeal. (Don’t be surprised if you hear some Janis Joplin and a cover of 24 Karat Magic.)

To top that off, there will also be live art installations happening that we are so stoked about! And more to come.

THE PERKS

A dope space is great, dope entertainment is great, but let’s be honest; dope food and drink are necessities.

In the spirit of the conference, this will be a cannabis-friendly and alcohol-free event with specialty CBD mocktails provided by Cannavis Syrup during the Psychedelics panel. And then once you’ve gotten your imbibe on, you’ll get an all organic Ayurvedic dinner provided by Ayur Ras. In addition, every attendee will receive a gift bag loaded with products from our sponsors.

Oh, and there’s some rumblings of an After After Party, too!

Details to be announced.

We’re in for quite an event! Hope to see you there.

If you still need to buy tickets , click this link and vibe on.

Cannabis Research Can Be a Battle but Dr. Jeff Chen Is Determined to Fight

Posted Posted in Blog

Cannabis medical research exists in a catch-22.

Because cannabis is a Schedule-1 drug, anyone attempting to study it scientifically has to climb a mountain of federal regulations and restrictions to conduct even limited research. At the same time, this lack of scientific evidence is often used by regulators and legislators as one of the reasons that cannabis should continue to be so heavily regulated.

There aren’t many people in the world who understand this paradox as well as Dr. Jeff Chen. While Dr. Chen is now the Director of the UCLA Cannabis Research Initiative, one of the first academic programs in the world dedicated to the study of cannabis, he began as a humble medical student skeptical of cannabis’ medical benefits. However, after seeing firsthand how cannabis benefited an epileptic patient he was inspired to dig deeper: 

Because cannabis is a Schedule-1 drug, anyone attempting to study it scientifically has to climb a mountain of federal regulations and restrictions to conduct even limited research. At the same time, this lack of scientific evidence is often used by regulators and legislators as one of the reasons that cannabis should continue to be so heavily regulated.

There aren’t many people in the world who understand this paradox as well as Dr. Jeff Chen. While Dr. Chen is now the Director of the UCLA Cannabis Research Initiative, one of the first academic programs in the world dedicated to the study of cannabis, he began as a humble medical student skeptical of cannabis’ medical benefits. However, after seeing firsthand how cannabis benefited an epileptic patient he was inspired to dig deeper: 

“I started coming across some really interesting animal studies on a variety of medical uses for cannabis. The light bulb went off that this was an area that clearly needed more science and research and that’s when I felt compelled to throw my hat in the ring and see what I could do to move the ball forward.”

That early epiphany set him on a path towards the forefront of cannabis medical science, and along the way he’s become thoroughly acquainted with the unique obstacles cannabis researchers face.

As mentioned above, cannabis’ Schedule-1 status means that researchers can’t touch any cannabis made inside the U.S. and instead have to rely solely on imports. And not only does this cannabis have to come from outside the US, it has to be produced as a pharmaceutical grade drug for the express purpose of research.

While this method of importing pharmaceutical grade cannabis has the benefit of passing the DEA’s restrictions, allowing for research to be done at all, Dr. Chen pointed out that it has several significant downsides. 

First, because they’re forced to use only cannabis extracts instead of entire plants, it’s extremely difficult for researchers to study areas like the much discussed but so far unproven idea of an “entourage effect.”

The presumption of the “entourage effect” is that consuming THC, CBD, and the other cannabinoids found naturally in the cannabis plant together versus separately results in a greater effect. It’s an idea that has the potential to shape the future of the cannabis industry and provide enormous benefit to patients, but proving it to be scientifically true would require direct comparisons of whole plants and isolates that current restrictions make nearly impossible.

And second, because the cost and bureaucracy involved in studying cannabis is so immense, Dr. Chen fears that only big pharmaceutical companies will be able to carry out crucial studies and that the potential benefits of the entire cannabis plant could be lost in the regulatory aftermath.

“There’s been very little to no research done on the cannabis plant. That’s why it’s really easy from a regulatory standpoint to say, why do we need the plant? Let’s just synthesize it and sell it in an FDA-approved fashion. 

 

So you could have a situation where over the next five years we have FDA-approved pharmaceutical versions available and they start phasing out every other use of the cannabis plant itself. I really hope not, because that would leave consumers stuck with limited, more expensive options.”

As Dr. Chen stressed, avoiding that limited future is going to require continued and substantial support for non-profit research, and it’s going to require cannabis scientists and manufacturers to work hand in hand. In his view, the more science drives the direction of the industry, the more benefits consumers will see, and the more comfortable regulators and legislators will be in allowing cannabis to be sold in a variety of forms, not just as a FDA-approved pharmaceutical.

As he said, “The more the industry can learn from newest science coming out and create products accordingly, the more beneficial and stable the industry will be over the long-run.” 


To hear Dr. Chen speak more about his work and vision for the future of medical cannabis in his keynote address, join us in Los Angeles on July 27 for a day devoted to exploring the intersection of cannahemp medical research and manufacturing technology.

Refocus on the Doctors, Researchers, and Scientists Healing Patients Through Cannabis

Posted 1 CommentPosted in Blog, Microscopes

1981: San Francisco activists routinely risk arrest to care for those dying in the throes of the AIDS crisis with cannabis.

2019: Cannabis billboards dot San Francisco’s skyline as brands maneuver for position in the newly minted Green Rush. 

While the current cannabis spotlight is increasingly focused on brands – an inevitable and in many ways positive sign of cannabis’ normalization – we can never forget that it was medical providers who laid down the foundation for the industry to exist at all, and who remain devoted to improving the lives of patients. 

It’s fair to say that in cannabis’ rapid rise into the mainstream the medical benefits of the plant have been sidelines in the national discussion, and so understandably that dynamic plays out at many cannabis conferences. We designed Microscopes and Machines to be a counterbalance to that trend, a chance to reprioritize the latest cannabis science and bring forward some of the extraordinary people doing that work: 

Dr. Jeff Chen: The Founder and Executive Director of the UCLA Cannabis Research Initiative, one of the first university programs in the world dedicated to the study of cannabis, Dr. Chen is a renowned physician, researcher, entrepreneur and speaker.

Dr. Sue Sisley: The Principal Investigator for the only FDA-approved randomized controlled trial examining safety/efficacy of whole plant marijuana in combat veterans suffering from PTSD. She is also suing the DEA over marijuana cultivation application delays.

Dr. Andrea Small-Howard: The Chief Science Officer at GB Sciences, Inc., Dr. Small-Howard is helping to create a novel drug discovery engine and biopharmaceutical drug development program for disease-specific, cannabis-based therapeutics.


This is a critical time for medical cannabis. FDA hearings on CBD and possible descheduling are underway. Big Pharma is making its move. The time is now to come together and figure out how to support scientific research in a way that honors the incredible healing potential of the plant, continues to keep the benefit of patients at the forefront, and inspires a new generation of researchers and medical professionals to pick up the torch and carry it into the future.  

We hope that you’ll join us for an opportunity to hear some of the most exciting new research happening. By uniting these two sides of cannabis – the microscopes and the machines – along with all of you, we truly believe that we can help build a cannabis industry that truly values people over profits.



Click this link to buy your tickets and learn more about our mission and the benefits of attending. 

Meet the People & Machines Building the Future of Cannabis Manufacturing

Posted Posted in Blog

Seemingly every day we read headlines about a new brand, and understandably so. As cannabis mainstreams, brands are the most accessible touchpoint for consumers. But those in the industry know that the real story, what will truly determine the future of cannabis, is playing out a level deeper – in the supply chain.



That’s precisely why we created the Machines portion of our conference, because if the cannabis industry is to actually reach that vaunted $60 billion a year in revenue projection, it will be because the supply chain has stabilized. After all, even the greatest brand in the world will fail without consistent access to safe, reliable, and approved product. 

Stabilizing that supply chain will depend on leaps forward in terms of technology and manufacturing processes – all with the approval of regulators – and behind those advancements are some of the best and brightest minds in cannabis, many of whom we’re honored to have as speakers:

Dustin Powers: The founder of GoodLifeGang and the Future4200 Forum, Dustin has gone on to pioneer multiple breakthroughs in the industry, from the beginnings of ethanol extraction to pesticide remediation.


Ace Shelander: The co-founder of Beaker & Wrench, Ace has brought wiped-film evaporation and machine design to a new level of excellence. His dosing pump made formerly unuseable machines useable and Beaker & Wrench is now releasing their own wiped-film evaporator. 

Dr. Wyeth Calloway, Ph.D:  Wyeth joined the Jetty Extracts team in 2017 where he has focused on analytics, operational efficiency, new product lines (including high purity d8), and more. As a result of his work, Jetty’s capacity has risen 10 times and is now one of the top 5 brands in CA.

Noah Cook: Noah is the President and Co-Founder at HZB Manufacturing in Los Angeles and is at the forefront of industrial cannabis applications in a regulatory environment. His work on ethanol extraction and recovery systems is now world renown.

We can say without exaggeration that this will be the first time this number and caliber of manufacturing experts will be in one place, and we expect their insights on topics like processing biomass and scaling while meeting regulations to be enormously valuable. These aren’t analysts or observers, these are the people actually building the machines and facilities the industry depend on, and consultations with them run in the thousands of dollars (if you can even get one).  

In addition, some of the technology being presented at the conference hasn’t been displayed before anywhere, giving attendees a sneak peek at some of the equipment that will help redefine what’s possible in cannabis manufacturing. 

This topic is both critically important and chronically overlooked by most cannabis conferences, and we hope you’ll join us for a day filled with actionable insights and guidance – purchase your tickets now. 

How Noah Cook Is Working to Solve Cannabis’ Quality at Scale Problem

Posted Posted in Blog

The world at large sees two primary images of cannabis. The grow – rows of cannabis plants growing under the sun or lights – and the final product. But just like any industry, there’s a small army of people between those two points without whom the entire system would collapse. We don’t often realize how complex the machine is, and how many cogs are involved, until we open it up.

Noah Cook is one of those crucial cogs. As one of the foremost experts on extraction, it’s Cook’s job to help make sure that farmers can produce high-quality product at scale while meeting the requirements of one of the most complex and quickly shifting regulatory environments in business.

Of course, Cook didn’t always know that he’d end up helping to build some of largest cannabis extraction facilities on the planet, but he did know his mother, and his mother was an inspiration. A recovered alcoholic who raised three kids by herself while getting her master’s degree, Cook’s mother went on to become a substance abuse counselor dedicated to helping people along their journey of healing.

Cook felt driven to follow in his mother’s footsteps and dedicate his life to helping others, but the road forward wasn’t immediately clear. The cost and amount of schooling involved in becoming a doctor seemed overwhelming, and not the best fit for his more engineering-leaning mind. And then in 2008 his home state of Michigan legalized cannabis, he became a licensed caregiver and discovered his passion.

“I started with small scale extractions for other small caregivers in Michigan, but there weren't enough caregivers and there wasn't enough material to really sustain any type of income. So I decided to move to California and put all my energy into large scale, cannabis concentrates that have the potential to provide medical benefits to the most people possible.”

Through a mix of dedication, constant learning and experimenting and outright hard work, Cook has been enormously successful in his mission, but knows better than almost anyone that the current challenges are still enormous.

From Cook’s perspective, the biggest problem facing the medical cannabis industry ties together both patients and cultivators: failed tests. Testing is necessary to protect patients, but cannabis processors are often drawing from five to ten farms to produce products and are simply unable to handle the complexity of subsequent of meeting very strict regulations, resulting in shortages that can endanger both patients, farms, and processors.

The best way for Cook to help patients then is to help these farms scale while meeting regulations, and despite the enormity of the task, he remains optimistic about a future where anyone who would benefit from cannabis has complete access to their medicine.

“Five years ago I would've said that not realistic with all the pushback. But I really see that now there's a lot of engaged players in this industry and people are really turning to science a lot more instead of conjecture.”

To hear more about how Cook and others in his field are working to make the machines that power natural medicines,  join us in Los Angeles on July 27 for a day devoted to exploring the intersection of cannahemp medical research and manufacturing technology.